- BioVie Inc BIVI announced topline results from an investigator-Sponsored Phase 2 trial of NE3107 for Alzheimer's Disease (AD).
- The company says that NE3107 is pursuing a two-pronged approach targeting neuroinflammation and insulin resistance.
- The trial enrolled a total of 23 patients. Initial results showed that the measurements for most patients improved with NE3107 treatment, although MCI/mild AD patients showed greater change.
- A large proportion of MCI/mild AD patients in the trial showed improvements with NE3107 compared to baseline as scored by the clinician (94% of 17 patients improved), the study partner (65% of 17 patients improved), and the patient (88% of 17 patients improved).
- NE3107 is associated with significant improvements in cognition, as evidenced by the ADAS-Cog12 scale. 82% of 17 patients experienced a 2.6-point decrease in ADAS-Cog12.
- 62% of 13 MCI/mild AD patients had decreased plasma TNF with a mean change of -0.55 pg/mL.
- Early analyses of imaging data suggest fundamental biological improvements in blood flow and reduced oxidative stress.
- No drug-related adverse events were reported.
- Price Action: BIVI shares are up 36.60% at $4.70 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in